Selective targeting of the AKT1 (E17K) mutation: advances in precision oncology and therapeutic design.

The AKT1 (E17K) mutation, associated with unfavourable outcomes in solid tumours, promotes cancer proliferation and persistence. A recent study by Gregory et al. discovered a reversible covalent inhibitor targeting this mutation, exhibiting significant anti-tumor action with little effects on normal cells. This advancement provides a targeted therapeutic approach for AKT-mutant malignancies and informs further inhibitor research.